178 related articles for article (PubMed ID: 30716118)
1. Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques.
Chong H; Xue J; Zhu Y; Cong Z; Chen T; Wei Q; Qin C; He Y
PLoS Pathog; 2019 Feb; 15(2):e1007552. PubMed ID: 30716118
[TBL] [Abstract][Full Text] [Related]
2. Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
Zhu Y; Chong H; Yu D; Guo Y; Zhou Y; He Y
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867304
[TBL] [Abstract][Full Text] [Related]
3. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
[TBL] [Abstract][Full Text] [Related]
4. Design of Novel HIV-1/2 Fusion Inhibitors with High Therapeutic Efficacy in Rhesus Monkey Models.
Chong H; Xue J; Zhu Y; Cong Z; Chen T; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2018 Aug; 92(16):. PubMed ID: 29899103
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Efficacy and Resistance Selection of a Lipopeptide Fusion Inhibitor in Simian Immunodeficiency Virus-Infected Rhesus Macaques.
Yu D; Xue J; Wei H; Cong Z; Chen T; Zhu Y; Chong H; Wei Q; Qin C; He Y
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404526
[TBL] [Abstract][Full Text] [Related]
6. Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus.
Zhu Y; Zhang X; Ding X; Chong H; Cui S; He J; Wang X; He Y
J Biol Chem; 2018 Apr; 293(14):5323-5334. PubMed ID: 29425101
[TBL] [Abstract][Full Text] [Related]
7. Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Chong H; Zhu Y; Yu D; He Y
J Virol; 2018 Oct; 92(20):. PubMed ID: 30089693
[TBL] [Abstract][Full Text] [Related]
8. Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide.
Xue J; Chong H; Zhu Y; Zhang J; Tong L; Lu J; Chen T; Cong Z; Wei Q; He Y
Cell; 2022 Jan; 185(1):131-144.e18. PubMed ID: 34919814
[TBL] [Abstract][Full Text] [Related]
9. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
Ding X; Zhang X; Chong H; Zhu Y; Wei H; Wu X; He J; Wang X; He Y
J Virol; 2017 Sep; 91(18):. PubMed ID: 28659478
[TBL] [Abstract][Full Text] [Related]
10. Protocol for evaluating CD8
Sun Y; Zhang J; Tong L; Lu J; Chen T; Wei Q; He Y; Cong Z; Xue J
STAR Protoc; 2022 Sep; 3(3):101479. PubMed ID: 35776642
[TBL] [Abstract][Full Text] [Related]
11. Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques.
Del Prete GQ; Smedley J; Macallister R; Jones GS; Li B; Hattersley J; Zheng J; Piatak M; Keele BF; Hesselgesser J; Geleziunas R; Lifson JD
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):163-8. PubMed ID: 26150024
[TBL] [Abstract][Full Text] [Related]
12. Polyethylene Glycol 40-Modified Peptide with High Therapeutic Efficacy in Simian-Human Immunodeficiency Virus-Acutely Infected Rhesus Monkeys.
Li M; Cheng S; Ding Y; Wang C; Feng Y; Wang W; Ma L; Li X
J Virol; 2020 Jul; 94(14):. PubMed ID: 32404523
[TBL] [Abstract][Full Text] [Related]
13. Broad-spectrum anti-HIV activity and high drug resistance barrier of lipopeptide HIV fusion inhibitor LP-19.
He L; Wang C; Zhang Y; Chong H; Hu X; Li D; Xing H; He Y; Shao Y; Hong K; Ma L
Front Immunol; 2023; 14():1199938. PubMed ID: 37256122
[TBL] [Abstract][Full Text] [Related]
14. Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying
Scinto HB; Gupta S; Thorat S; Mukhtar MM; Griffiths A; Delgado J; Plake E; Vyas HK; Strickland A; Byrareddy SN; Montefiori DC; LaBranche C; Pal R; Treece J; Orndorff S; Ferrari MG; Weiss D; Chenine AL; McLinden R; Michael N; Kim JH; Robb ML; Rerks-Ngarm S; Pitisuttithum P; Nitayaphan S; Ruprecht RM
J Virol; 2018 Jul; 92(14):. PubMed ID: 29743361
[TBL] [Abstract][Full Text] [Related]
15. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
16. Development of potent and long-acting HIV-1 fusion inhibitors.
Chong H; Wu X; Su Y; He Y
AIDS; 2016 May; 30(8):1187-96. PubMed ID: 26919736
[TBL] [Abstract][Full Text] [Related]
17. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
[TBL] [Abstract][Full Text] [Related]
18. Short- and long-term clinical outcomes in rhesus monkeys inoculated with a highly pathogenic chimeric simian/human immunodeficiency virus.
Endo Y; Igarashi T; Nishimura Y; Buckler C; Buckler-White A; Plishka R; Dimitrov DS; Martin MA
J Virol; 2000 Aug; 74(15):6935-45. PubMed ID: 10888632
[TBL] [Abstract][Full Text] [Related]
19. Mucosal T Helper 17 and T Regulatory Cell Homeostasis Correlate with Acute Simian Immunodeficiency Virus Viremia and Responsiveness to Antiretroviral Therapy in Macaques.
O'Connor MA; Munson PV; Tunggal HC; Hajari N; Lewis TB; Bratt D; Moats C; Smedley J; Bagley KC; Mullins JI; Fuller DH
AIDS Res Hum Retroviruses; 2019 Mar; 35(3):295-305. PubMed ID: 30398361
[TBL] [Abstract][Full Text] [Related]
20. Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1.
North TW; Van Rompay KK; Higgins J; Matthews TB; Wadford DA; Pedersen NC; Schinazi RF
J Virol; 2005 Jun; 79(12):7349-54. PubMed ID: 15919889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
